Literature DB >> 8110876

Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia.

G Gaidano1, A Serra, A Guerrasio, G Rege-Cambrin, U Mazza, G Saglio.   

Abstract

We have investigated the involvement of the p53 and RB1 tumor-suppressor genes in 26 cases of chronic myeloid leukemia (CML) blast crisis, including 17 myeloid, eight lymphoid, and one megakaryoblastic crisis. The presence of p53 mutations in exons 5 through 9 was tested by the PCR-single-strand conformation polymorphism (SSCP) assay, followed by PCR-direct sequencing; in addition, loss of heterozygosity (LOH) at 17p13, the site of the p53 gene, was assayed by Southern blot. Given the variability of the mechanisms of inactivation of the RB1 gene in human tumors, a combination of Southern blot and mutational analysis by PCR-SSCP was used. p53 mutations were restricted to one case of myeloid blast crisis, showing a CGC-->TGC (Arg-->Cys) mutation at codon 283; two additional cases displayed LOH at 17p13 in the absence of p53 mutations. No molecular lesions of the RB1 gene were detected in any of the cases analyzed. These data indicate that inactivation of p53 and RB1 is a rare event in the molecular pathogenesis of CML acute transformation.

Entities:  

Mesh:

Year:  1994        PMID: 8110876     DOI: 10.1007/bf01695912

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  32 in total

1.  Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p.

Authors:  H Nakai; S Misawa; J Toguchida; D W Yandell; K Ishizaki
Journal:  Cancer Res       Date:  1992-12-01       Impact factor: 12.701

2.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

Review 3.  Role of the retinoblastoma gene in the initiation and progression of human cancer.

Authors:  W F Benedict; H J Xu; S X Hu; R Takahashi
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

4.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

Authors:  G Gaidano; P Ballerini; J Z Gong; G Inghirami; A Neri; E W Newcomb; I T Magrath; D M Knowles; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

5.  Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; S H Advani; S Benchimol; M J Cline
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

6.  Localization of gene for human p53 tumour antigen to band 17p13.

Authors:  M Isobe; B S Emanuel; D Givol; M Oren; C M Croce
Journal:  Nature       Date:  1986 Mar 6-12       Impact factor: 49.962

Review 7.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

8.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

9.  Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia.

Authors:  M Towatari; K Adachi; H Kato; H Saito
Journal:  Blood       Date:  1991-11-01       Impact factor: 22.113

10.  p53 gene rearrangements in chronic myelocytic leukemia.

Authors:  A Hernández; P Hernández; L Corral; A Muñiz; C Alaez; E Espinosa; O Fernández; G Martinez
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

View more
  3 in total

Review 1.  Biotherapy of chronic myelogenous leukemia.

Authors:  W E Aulitzky; C Peschel; F Schneller; C Huber
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

2.  P53 tumor suppressor gene in chronic myelogenous leukemia: a sequential study.

Authors:  A Rovira; A Urbano-Ispizua; F Cervantes; M Rozman; J L Vives-Corrons; E Montserrat; C Rozman
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

3.  Deletions of the region 17p11-13 in advanced melanoma revealed by cytogenetic analysis and fluorescence in situ hybridization.

Authors:  I Okamoto; H Pirc-Danoewinata; J Ackermann; J Drach; H Schlagbauer Wadl; B Jansen; K Wolff; H Pehamberger; C Marosi
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.